Ph.D. Jay R. Luly - 15 Sep 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: President and CEO, Director
Signature: /s/ Nathanial S. Gardiner as attorney-in-fact
Issuer symbol: ENTA
Transactions as of: 15 Sep 2021
Net transactions value: -$266,698
Form type: 4
Filing time: 17 Sep 2021, 17:17:30 UTC
Next filing: 23 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Sale	$266,698	-4,516	-0.66%	$59.06	676,972	15 Sep 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2020.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.23, inclusive.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 above.